Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 2/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PNMT | P11086 | 1/20 | 0.41 |
| ▸ | UGT2B17 | O75795 | 2/20 | 0.40 |
| ▸ | HTR2C | P28335 | 2/20 | 0.39 |
| ▸ | CMA1 | P23946 | 2/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.36 |
| ▸ | RBP4 | P02753 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29668889 | 0.90 | CYP11B1 (0.44) | CYP11B1CYP11B2GAATDP1PNMT | |
| SCHEMBL29878084 | 0.90 | CYP11B1 (0.44) | CYP11B1CYP11B2GAATDP1PNMT | |
| SCHEMBL1508485 | 0.90 | CYP11B1 (0.44) | CYP11B1CYP11B2GAATDP1PNMT | |
| SCHEMBL1508513 | 0.90 | CYP11B1 (0.44) | CYP11B1CYP11B2GAATDP1PNMT | |
| SCHEMBL15531953 | 0.90 | CYP11B1 (0.44) | CYP11B1CYP11B2GAATDP1PNMT | |
| SCHEMBL16729403 | 0.80 | PNMT (0.41) | GAATDP1PNMTHTR2CCMA1 | |
| SCHEMBL15335677 | 0.80 | PNMT (0.47) | CYP11B1CYP11B2GAATDP1PNMT | |
| SCHEMBL15335679 | 0.80 | PNMT (0.47) | CYP11B1CYP11B2GAATDP1PNMT | |
| SCHEMBL2422836 | 0.77 | UGT2B17 (0.47) | CYP11B1CYP11B2GAAKMT2AUGT2B17 | |
| SCHEMBL18410118 | 0.77 | S1PR1 (0.38) | CYP11B1CYP11B2GAATDP1PNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200061063-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-02-27 | — | — | US | disclosed |
| CN-106983751-B | Bicyclic substituted uracils and their use | 拜耳医药股份有限公司 | 2020-01-07 | — | — | CN | disclosed |
| US-10300062-B2 | Bicyclically substituted uracils and the use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-05-28 | — | — | US | disclosed |
| US-20180256576-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-09-13 | — | — | US | disclosed |
| US-9949977-B2 | Bicyclically substituted uracils and the use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-04-24 | — | — | US | disclosed |
| US-9949978-B2 | Bicyclically substituted uracils and the use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-04-24 | — | — | US | disclosed |
| EP-3045456-B1 | BICYCLIC SUBSTITUTED URACILS AND THEIR USE | Bayer Pharma AG (DE) | 2017-10-25 | — | — | EP | disclosed |
| US-9751843-B2 | Substituted uracils and use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-05 | — | — | US | disclosed |
| US-20170020875-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-01-26 | — | — | US | disclosed |
| US-20170020876-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-01-26 | — | — | US | disclosed |
| US-20150148340-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-05-28 | — | — | US | disclosed |
| WO-2015067650-A1 | SUBSTITUTED 1,2,4-TRIAZINE-3,5-DIONES AND THE USE THEREOF AS CHYMASE INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-05-14 | — | — | WO | disclosed |
| WO-2015067650-A1 | SUBSTITUTED 1,2,4-TRIAZINE-3,5-DIONES AND THE USE THEREOF AS CHYMASE INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-05-14 | — | — | WO | disclosed |
| WO-2015067630-A1 | SUBSTITUTED URACILS AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-05-14 | — | — | WO | disclosed |
| EP-2847190-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2015-03-18 | — | — | EP | disclosed |
| EP-2289868-B1 | CARBOXYLIC ACID COMPOUND | DAIICHI SANKYO CO LTD (JP) | 2014-08-13 | — | — | EP | disclosed |
| WO-2013167495-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-11-14 | — | — | WO | disclosed |
| US-8222281-B2 | Carboxylic acid compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-07-17 | — | — | US | disclosed |
| US-20110053974-A1 | CARBOXYLIC ACID COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-03 | — | — | US | disclosed |
| EP-2289868-A1 | CARBOXYLIC ACID COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2011-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053974-A1 | CARBOXYLIC ACID COMPOUND | AKR1C3, SLC5A1, GPR119 | CYP11B1 79/4885CYP11B2 106/4885GAA 951/4885 |
| US-20170020875-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | UNG, UMPS, TYMP | CYP11B1 529/4885CYP11B2 406/4885GAA 517/4885 |
| US-20170020876-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | UNG, UMPS, TYMP | CYP11B1 529/4885CYP11B2 406/4885GAA 517/4885 |
| US-10300062-B2 | Bicyclically substituted uracils and the use thereof | UNG, UMPS, TYMP | CYP11B1 529/4885CYP11B2 406/4885GAA 517/4885 |
| US-20200061063-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | UNG, UMPS, TYMP | CYP11B1 529/4885CYP11B2 406/4885GAA 517/4885 |
| US-20150148340-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | UNG, UMPS, TYMP | CYP11B1 529/4885CYP11B2 406/4885GAA 517/4885 |
| US-20180256576-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | UNG, UMPS, TYMP | CYP11B1 529/4885CYP11B2 406/4885GAA 517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.